




The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Rigel Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is 136%, being 77% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	99,266
Cost of Goods Sold	7,110
Intangible Assets	0
Liabilities, Current	53,267
Liabilities, Non-Current	40,229
Other Assets	17,794
Other Compr. Net Income	161
Other Expenses	6,872
Other Liabilities	52,373
Other Net Income	2,272
Other Revenues	116,882
Property and Equipment	165
Research and Development	24,522
Selling, General and Administrative Expense	105,741

Output Variable	Value in 1000 USD
Assets	117,225
Liabilities	145,869
Expenses	144,245
Revenues	116,882
Stockholders Equity	-28,644
Net Income	-25,091
Comprehensive Net Income	-25,010
BaseVar	263,327
ECR before LimitedLiability	-66%
Economic Capital Ratio	136%